BF Biosciences Limited (PSX: BFBIO)
Pakistan
· Delayed Price · Currency is PKR 209.19
-4.22 (-1.98%)
At close: Feb 4, 2025
BF Biosciences Income Statement
Financials in millions PKR. Fiscal year is July - June.
Millions PKR. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | Jun '20 Jun 30, 2020 | 2019 |
| Revenue | 4,080 | 3,659 | 1,810 | 1,521 | 1,755 | 628.29 | Upgrade
|
| Revenue Growth (YoY) | 168.32% | 102.19% | 18.99% | -13.34% | 179.30% | 40.10% | Upgrade
|
| Cost of Revenue | 2,364 | 2,128 | 1,362 | 1,063 | 958.33 | 541.83 | Upgrade
|
| Gross Profit | 1,716 | 1,531 | 447.24 | 457.77 | 796.47 | 86.45 | Upgrade
|
| Selling, General & Admin | 887.29 | 755.61 | 158.5 | 187.12 | 152.55 | 61.35 | Upgrade
|
| Other Operating Expenses | 105.85 | 64.01 | 19.46 | 28.42 | 42.73 | 10.28 | Upgrade
|
| Operating Expenses | 993.14 | 819.62 | 177.96 | 215.54 | 195.29 | 71.63 | Upgrade
|
| Operating Income | 723.03 | 711.15 | 269.29 | 242.23 | 601.18 | 14.82 | Upgrade
|
| Interest Expense | - | -1.51 | -1.22 | -65.62 | -25.27 | -1.18 | Upgrade
|
| Interest & Investment Income | 24.1 | 19.34 | 83.4 | 141 | 39 | 45 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.11 | -0.11 | -8.18 | 28.15 | 28.7 | 0.29 | Upgrade
|
| Other Non Operating Income (Expenses) | -149.33 | -149.33 | -151.08 | - | - | - | Upgrade
|
| EBT Excluding Unusual Items | 597.69 | 579.54 | 192.21 | 345.76 | 643.61 | 58.94 | Upgrade
|
| Gain (Loss) on Sale of Investments | 0.21 | 0.21 | 8.93 | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 2.13 | 2.13 | 1.06 | 3 | 2 | 1 | Upgrade
|
| Pretax Income | 600.03 | 581.88 | 202.2 | 348.76 | 645.61 | 59.94 | Upgrade
|
| Income Tax Expense | 200.11 | 196.47 | 53.14 | 41.78 | 37.62 | 12.83 | Upgrade
|
| Net Income | 399.91 | 385.41 | 149.05 | 306.98 | 607.99 | 47.11 | Upgrade
|
| Net Income to Common | 399.91 | 385.41 | 149.05 | 306.98 | 607.99 | 47.11 | Upgrade
|
| Net Income Growth | 30.27% | 158.57% | -51.45% | -49.51% | 1190.62% | - | Upgrade
|
| Shares Outstanding (Basic) | 63 | 63 | 63 | 63 | 63 | 63 | Upgrade
|
| Shares Outstanding (Diluted) | 63 | 63 | 63 | 63 | 63 | 63 | Upgrade
|
| Shares Change (YoY) | -0.01% | - | 0.01% | - | - | - | Upgrade
|
| EPS (Basic) | 6.32 | 6.09 | 2.35 | 4.85 | 9.60 | 0.74 | Upgrade
|
| EPS (Diluted) | 6.32 | 6.09 | 2.35 | 4.85 | 9.60 | 0.74 | Upgrade
|
| EPS Growth | 30.29% | 158.58% | -51.45% | -49.51% | 1190.62% | - | Upgrade
|
| Free Cash Flow | 254.42 | 518.57 | -2,164 | -952 | -371 | -42 | Upgrade
|
| Free Cash Flow Per Share | 4.02 | 8.19 | -34.18 | -15.03 | -5.86 | -0.66 | Upgrade
|
| Gross Margin | 42.06% | 41.84% | 24.72% | 30.10% | 45.39% | 13.76% | Upgrade
|
| Operating Margin | 17.72% | 19.44% | 14.88% | 15.93% | 34.26% | 2.36% | Upgrade
|
| Profit Margin | 9.80% | 10.53% | 8.24% | 20.19% | 34.65% | 7.50% | Upgrade
|
| Free Cash Flow Margin | 6.24% | 14.17% | -119.61% | -62.60% | -21.14% | -6.68% | Upgrade
|
| EBITDA | 766.09 | 747.27 | 303.61 | 270.23 | 624.18 | 36.82 | Upgrade
|
| EBITDA Margin | 18.78% | 20.42% | 16.78% | 17.77% | 35.57% | 5.86% | Upgrade
|
| D&A For EBITDA | 43.06 | 36.12 | 34.33 | 28 | 23 | 22 | Upgrade
|
| EBIT | 723.03 | 711.15 | 269.29 | 242.23 | 601.18 | 14.82 | Upgrade
|
| EBIT Margin | 17.72% | 19.44% | 14.88% | 15.93% | 34.26% | 2.36% | Upgrade
|
| Effective Tax Rate | 33.35% | 33.76% | 26.28% | 11.98% | 5.83% | 21.41% | Upgrade
|
| Advertising Expenses | - | 149.49 | 32.03 | 17 | 16 | 4 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.